Physician profile
Jon J Tumen
NPI 1831139799
$16,066.46
in general payments reported to CMS, 2019-2025
36 companies · $19.75 in 2025
The $19.75 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,196 · 2020: $2,228 · 2021: $2,410 · 2022: $2,810 · 2023: $2,935 · 2024: $2,468 · 2025: $19.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,422.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,610.47 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $2,223.61 | 2019-2024 | Fasenra, Airsupra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $1,880.70 | 2019-2024 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $1,668.47 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $1,118.01 | 2019-2024 | Arikayce |
| Grifols USA, LLC | $910.42 | 2019-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $701.42 | 2019-2024 | |
| Mylan Specialty L.P. | $593.38 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $578.61 | 2019-2024 | Tyvaso |
| Electromed, INC. | $559.70 | 2019-2024 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $557.90 | 2019-2024 | Dupixent |
| Pfizer INC. | $367.15 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $336.16 | 2019-2024 | Recarbrio, Zerbaxa, Winrevair |
| Amgen INC. | $262.29 | 2022-2024 | Tezspire, Tavneos |
| Inspire Medical Systems, INC. | $199.95 | 2019-2024 | Inspire |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $196.42 | 2022-2024 | Hyqvia, Glassia |
| Axsome Therapeutics, INC. | $168.90 | 2022-2024 | Sunosi |
| Genentech USA, INC. | $155.69 | 2019-2023 | Xolair |
| Janssen Pharmaceuticals, INC | $137.54 | 2021-2024 | Xarelto |
| Inari Medical, INC. | $133.35 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Jazz Pharmaceuticals INC. | $82.30 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.04 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $73.47 | 2019 | |
| Mallinckrodt Enterprises LLC | $68.99 | 2019 | |
| Vifor Pharma, INC. | $68.72 | 2024-2025 | Zemaira |
| Novartis Pharmaceuticals Corporation | $62.74 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $50.72 | 2019-2021 | |
| Pulmonx Corporation | $40.42 | 2022-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Circassia INC. | $33.31 | 2019 | |
| Boston Scientific Corporation | $26.88 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.61 | 2020 | |
| Ani Pharmaceuticals, INC. | $23.59 | 2024 | Purified Cortrophin Gel |
| Baxter Healthcare | $23.47 | 2022 | |
| Philips North America LLC | $19.25 | 2022 | |
| Shire North American Group INC | $18.17 | 2019 | |
| Allergan, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Tumen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.